No
Gender
Age
AF-type
AF duration (months) History of transplantation (years) AST IU/L ALT IU/L Scr μmol/L
Anti-rejection drugs
Anticoagulants
Patients with liver transplantation (1-5) Patients with liver transplantation (1-5) Patients with liver transplantation (1-5) Patients with liver transplantation (1-5) Patients with liver transplantation (1-5) Patients with liver transplantation (1-5) Patients with liver transplantation (1-5) Patients with liver transplantation (1-5) Patients with liver transplantation (1-5) Patients with liver transplantation (1-5) Patients with liver transplantation (1-5)
1 Male 62 PeAF 24 10 34 30 - TAC+MMF Rivaroxaban
2 Male 48 PAF 24 10 24 40 - CsA+MMF Rivaroxaban
3 Male 69 PAF 11 13 21 20 - TAC+MMF Rivaroxaban
4 Female 65 PAF 48 9 20 13 - CS+TAC Rivaroxaban
5 Male 61 PAF 156 10 25 20 - TAC Warfarin
Patients with kidney transplantation (6-14) Patients with kidney transplantation (6-14) Patients with kidney transplantation (6-14) Patients with kidney transplantation (6-14) Patients with kidney transplantation (6-14) Patients with kidney transplantation (6-14) Patients with kidney transplantation (6-14) Patients with kidney transplantation (6-14) Patients with kidney transplantation (6-14) Patients with kidney transplantation (6-14) Patients with kidney transplantation (6-14)
6 Male 63 PeAF 84 5 - - 90.4 TAC+MMF Rivaroxaban
7 Male 57 PeAF 120 11 - - 88.8 CS+SRL+MMF Dabigatran
8 Male 58 PAF 60 4 - - 81.3 CS+TAC+MMF Rivaroxaban
9 Male 50 PAF 24 20 - - 160.5 TAC+MMF Rivaroxaban
10 Male 56 PAF 24 7 - - 78.8 CS+TAC+MMF Warfarin
11 Male 59 PAF 2 9 - - 86.8 CS+CsA+MMF Warfarin
12 Female 62 PAF 12 23 - - 69.3 CS+CsA+Aza Warfarin
13 Female 58 PAF 60 4 - - 70.1 CS+CsA+MMF Rivaroxaban
14 Male 58 PAF 18 9 - - 78.5 CS+TAC+MMF Warfarin